Coronaridine congeners inhibit human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites

Alper, 2008, The ibogaine medical subculture, J. Ethnopharmacol., 115, 9, 10.1016/j.jep.2007.08.034 Arias, 2013, Mecamylamine inhibits muscle nicotinic acetylcholine receptors by competitive and noncompetitive mechanisms, OA Biochem., 1, 7, 10.13172/2052-9651-1-1-600 Arias, 2012, Structural and functional interaction of (±)-2-(N-tert-butylamino)-3′-iodo-4′-azidopropiophenone, a photoreactive bupropion derivative, with nicotinic acetylcholine receptors, Neurochem. Int., 61, 1433, 10.1016/j.neuint.2012.10.011 Arias, 2011, Structure–activity relationship of ibogaine analogs interacting at nicotinic acetylcholine receptors in different conformational states, Int. J. Biochem. Cell Biol., 43, 1330, 10.1016/j.biocel.2011.05.011 Arias, 2010, Catharanthine alkaloids are noncompetitive antagonists of muscle nicotinic acetylcholine receptors, Neurochem. Int., 57, 153, 10.1016/j.neuint.2010.05.007 Arias, 2010, Interaction of 18-methoxycoronaridine with muscle nicotinic receptors in different conformational states, Biochem. Biophys. Acta, 1798, 1153, 10.1016/j.bbamem.2010.03.013 Arias, 2010, Interaction of ibogaine with human α3β4-nicotinic receptors in different conformational states, Int. J. Biochem. Cell Biol., 42, 1525, 10.1016/j.biocel.2010.05.011 Arias, 2010, Different interaction between tricyclic antidepressants and mecamylamine with the human α3β4 nicotinic acetylcholine receptor ion channel, Neurochem. Int., 56, 642, 10.1016/j.neuint.2010.01.011 Badio, 1997, Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors, Mol. Pharmacol., 51, 1, 10.1124/mol.51.1.1 Bondarenko, 2013, NMR resolved multiple anesthetic binding sites in the TM domains of the α4β2 nAChR, Biochim. Biophys. Acta, 1828, 398, 10.1016/j.bbamem.2012.09.014 Carnicella, 2010, Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration, Addict. Biol., 15, 424, 10.1111/j.1369-1600.2010.00251.x Cheng, 1973, Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction, Biochem. Pharmacol., 22, 3099, 10.1016/0006-2952(73)90196-2 Eisenberg, 1997, VERIFY3D: assessment of protein models with three-dimensional profiles, Methods Enzymol., 277, 396, 10.1016/S0076-6879(97)77022-8 Eswar, 2006, Comparative protein structure modeling using Modeller, Curr. Protoc. Bioinform., Suppl. 15, 1.6.30 Fryer, 1999, Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine, J. Pharmacol. Exp. Ther., 288, 88 Gasteiger, 2003, ExPASy: the proteomics server for in-depth protein knowledge and analysis, Nucleic Acids Res., 31, 3784, 10.1093/nar/gkg563 Glick, 2002, Modulation of nicotine self-administration in rats by combination therapy with agents blocking α3β4 nicotinic receptors, Eur. J. Pharmacol., 448, 185, 10.1016/S0014-2999(02)01944-1 Glick, 2002, Antagonism of α3β4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration, Eur. J. Pharmacol., 438, 99, 10.1016/S0014-2999(02)01284-0 Glick, 1996, Ibogaine-like effects of noribogaine in rats, Brain Res., 713, 294, 10.1016/0006-8993(95)01563-9 Laskowski, 1993, PROCHECK: a program to check the stereochemical quality of protein structures, J. Appl. Cryst., 26, 283, 10.1107/S0021889892009944 Maisonneuve, 2003, Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment, Pharmacol. Biochem. Behav., 75, 07, 10.1016/S0091-3057(03)00119-9 Mash, 2000, Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures, Ann. N.Y. Acad. Sci., 914, 394, 10.1111/j.1749-6632.2000.tb05213.x McCallum, 2012, α3β4 nicotinic acetylcholine receptors in the medial habenula modulate the mesolimbic dopaminergic response to acute nicotine in vivo, Neuropharmacology, 3, 434, 10.1016/j.neuropharm.2012.04.015 Nury, 2011, X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel, Nature, 469, 428, 10.1038/nature09647 Obach, 1998, Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine, Drug Metab. Dispos., 26, 764 Ortells, 2010, Neuronal networks of nicotine addiction, Int. J. Biochem. Cell Biol., 42, 1931, 10.1016/j.biocel.2010.08.019 Pace, 2004, Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration, Eur. J. Pharmacol., 492, 159, 10.1016/j.ejphar.2004.03.062 Richmond, 2006, GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D, J. Comput. Aided Mol. Des., 20, 567, 10.1007/s10822-006-9082-y Thompson, 1994, CLUSTAL W: improving the sensitivity of progressive multiple sequence Alignment through sequence weighting, position-specific gap penalties and weight matrix choice, Nucleic Acids Res., 22, 4673, 10.1093/nar/22.22.4673 Unwin, 2005, Refined structure of the nicotinic acetylcholine receptor at 4Å resolution, J. Mol. Biol., 346, 967, 10.1016/j.jmb.2004.12.031 Zhang, 2002, Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19, Drug Metab. Dispos., 30, 663, 10.1124/dmd.30.6.663